Two fundamentally different approaches to the same problem

The most immediate question for anyone weighing these two options is straightforward: does treatment mean an operation, or an injection?

Microfracture is a surgical procedure performed under general anaesthetic in an operating theatre. The surgeon uses a fine pick or awl to drill small holes through the subchondral bone plate — the hard layer beneath the cartilage surface — so that marrow cells bleed into the defect and form a clot. It requires hospital admission and formal surgical recovery.

ChondroFiller injection takes a different path entirely. The collagen scaffold is delivered as an ultrasound-guided outpatient injection — no incision, no general anaesthetic, and no penetration of the underlying bone. Patients are treated and go home the same day.

Both approaches target focal cartilage defects, and both have a role in the cartilage-repair pathway. Which is appropriate depends on defect size, the condition of the surrounding joint, and whether other surgical work is already on the table for different reasons. For patients whose defect is small, mechanically stable, and otherwise uncomplicated, the procedural difference alone — theatre versus clinic — is often a significant factor in the decision.

What microfracture does — and why fibrocartilage wears out

The clot that forms after microfracture is both the treatment's mechanism and the source of its durability ceiling.

Once the surgeon's awl has opened channels through the subchondral bone plate, blood and marrow elements fill the defect and coagulate. Mesenchymal stem cells within that clot then differentiate and deposit new tissue — but what they produce is fibrocartilage rather than the native hyaline cartilage it is meant to replace. The structural difference is compositional: fibrocartilage is dominated by Type I collagen and is notably deficient in glycosaminoglycans (GAGs), the molecules that bind water within the cartilage matrix and allow it to absorb and redistribute compressive load.

Without adequate GAG content, repair tissue is far less resilient under the cyclical pressures of walking, stair-climbing, and sport. Deterioration tends to be progressive rather than abrupt: the critical failure window sits broadly between two and five years post-procedure. A pooled dataset recorded a 62% treatment failure rate at a median follow-up of four years — a figure that reflects a biological ceiling inherent to fibrocartilage, not a shortcoming of surgical execution.

Microfracture has a long and well-established track record in cartilage surgery and retains a recognised place in the treatment landscape. Its limitation is mechanistic: a procedure that reliably generates fibrocartilage can only be as durable as the tissue it creates, and fibrocartilage was not designed to carry the loads of a healthy articular surface.

How ChondroFiller injection works as a scaffold

Once the collagen scaffold is injected under ultrasound guidance into the cartilage defect, the repair process unfolds inside the joint itself.

ChondroFiller is a cell-free Type I collagen hydrogel — no cells are loaded into it before the injection. Within minutes of placement, the scaffold self-polymerises into a stable matrix that occupies the defect. Progenitor cells from the surrounding synovium and adjacent tissue then migrate into this matrix over the following weeks. The process is described as acellular matrix-induced chondrogenesis: the scaffold provides the structural environment; the patient's own cells do the biological work of depositing new cartilage matrix. Crucially, the subchondral bone is left entirely intact — a point that distinguishes this mechanism from the marrow-clot pathway described in the previous section.

The cell-recruitment mechanism has been confirmed directly in a 2025 ex vivo osteochondral explant study, which recorded a 2.4-fold increase in DNA content by day 14 in ChondroFiller-treated defects compared with untreated controls — evidence of active progenitor cell migration into the scaffold. Over 6–12 months, this process matures toward hyaline-like cartilage rather than fibrocartilage, and the MRI findings reflect that difference: published MOCART integration scores of 81–84 have been reported in treated cohorts, compared with approximately 27 in microfracture series.

One clinical implication follows directly from the scaffold's biology. A 2024 biomechanical in-vitro study found that before the matrix has had time to stabilise, ChondroFiller could not adequately reduce stress transmitted to opposing cartilage under cyclic loading. This is the mechanistic basis for the clinical protocol of progressive weight-bearing over approximately six weeks post-injection — the restriction exists to allow the scaffold time to mature before full joint loads are applied, and reflects a considered understanding of how the material behaves rather than a limitation of the approach itself.

What the clinical evidence shows

The strongest direct comparison between the two approaches comes from a 2016 prospective RCT (n=23) that randomised patients to either ChondroFiller liquid or microfracture. IKDC scores in the ChondroFiller group improved significantly at 3, 6, and 12 months (p<0.05). The trial's limitation is equally important to state: six of the ten patients allocated to microfracture refused surgery before treatment, producing a 60% attrition rate that makes cross-arm statistical conclusions unreliable. The study confirms a clinical signal for ChondroFiller but cannot settle the comparative question on its own.

The MOCART imaging figures referenced in the previous section — 81–84 for ChondroFiller versus approximately 27 for microfracture — carry a methodological caveat worth naming plainly: they derive from separate cohort studies with heterogeneous patient populations, not from a single controlled trial. The consistency of the direction is notable; direct numerical equivalence cannot be assumed. No sufficiently powered head-to-head randomised trial has been published to date.

Longer-term cohort data place ChondroFiller reoperation rates at 3–8%, with functional scores sustained or continuing to improve at three years — a trajectory that contrasts with the decline documented in microfracture series across the same follow-up window.

One finding with immediate practical weight concerns application precision. A study of ChondroFiller used in distal radius chondral defects found that flush, correctly filled applications produced significantly better cartilage quality at follow-up arthroscopy than overfilled ones (Outerbridge grade 1.5 versus 3, p=0.006; ICRS grade 1 versus 3, p=0.002); overfilling produced fibrous rather than hyaline-like tissue. This precision requirement — not inherent in the microfracture technique — is one reason that outcomes from the same product can differ depending on the experience of the practitioner delivering it.

Which patients suit each pathway

Choosing between these two pathways depends less on preference than on a cluster of clinical criteria that a specialist can assess from imaging and history.

Both approaches are designed for focal, mechanically stable cartilage defects rather than diffuse joint degeneration. The ChondroFiller injection has been applied to defects exceeding 2 cm² — including acetabular lesions in the hip — and to defects as small as 0.5 mm in the wrist, so lesion size alone is rarely a disqualifying factor for the injection route. What does disqualify patients clearly is pre-existing osteoarthritis. A hip arthroscopy cohort followed for 12–60 months found that patients with Tönnis grade 2–3 OA had uniformly poor outcomes after ChondroFiller gel placement, while those without background degeneration did well. Asking a clinician for your Tönnis grade — or equivalent OA grading in other joints — is a practical first step for any patient considering this pathway.

Younger, active patients with a small, isolated defect and no background degeneration are biologically suited to either route. The structural distinction matters here: because the ChondroFiller injection leaves the subchondral bone plate untouched, it does not compromise the architecture needed for later surgical options should they ever become necessary. Microfracture, by penetrating the bone plate, forecloses some of those options.

Microfracture retains a legitimate role when a patient is already undergoing arthroscopy for a separate indication — a loose body, a meniscal tear — and a focal chondral defect is found at the same time. Combining cartilage treatment with a planned procedure avoids a second anaesthetic and is a sound clinical rationale.

For patients with large, unstable Grade III–IV focal defects already requiring keyhole surgery, ChondroFiller can also be placed intra-operatively as part of an augmented chondrogenesis procedure — a surgical context distinct from the standard outpatient injection pathway.

Assessing your suitability at London Cartilage Clinic

For UK patients whose defect profile fits the criteria described above, the practical next step is an assessment that maps imaging findings to the injection pathway — or determines that a different route is more appropriate.

At the London Cartilage Clinic on Harley Street, that assessment covers imaging review, defect characterisation by size and depth, joint-loading status, and a frank discussion of whether the outpatient ChondroFiller injection, a surgical approach, or a combination strategy best fits the individual presentation. Patients with background osteoarthritis are typically advised at that stage that the injection pathway is unlikely to produce durable benefit — a conclusion grounded in the cohort data reviewed in the preceding sections rather than in clinical caution alone.

Practitioner experience is a material factor in this particular treatment. Because application precision — specifically fill volume — directly influences tissue quality, the clinician delivering the injection carries more technical weight than in some comparable procedures. Professor Paul Y. F. Lee leads ChondroFiller delivery at the clinic.

Assessments can be arranged via londoncartilage.com.

1. [1] A Novel Strategy to Enhance Microfracture Treatment With Stromal Cell-Derived Factor-1 in a Rat Model. (2021). https://doi.org/10.3389/fcell.2020.595932 https://doi.org/10.3389/fcell.2020.595932
2. [2] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Arthroscopic utilization of ChondroFiller gel for hip articular cartilage defects: cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
6. [6] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
7. [7] Implantation of ChondroFiller Liquid® as a scaffold for chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936